Abionic Company

Abionic SA is ideally positioned at the boundaries of medical technology, biotechnology and nanotechnology. As a spin-off from EPFL (Swiss Federal Institute of Technology Lausanne, Switzerland), Abionic uses these highly advanced technologies to provide the medical profession with a novel diagnostic tool designed to give patients personal allergy profiles. Abionic aims to become an important international player in the field of personalized medicine, in particular in allergy detection. Abionic SA is a certified ISO 9001/13485 company, including research, development and commercialization of in vitro diagnostic devices for allergies detection. The standard ISO 13485 specifies requirements for a quality management system where an organization has to demonstrate its ability to provide medical devices and related services that consistently meet customer and regulatory requirements.
Technology: P4 Medicine
Industry: P4 Medicine
Headquarters: Lausanne, Vaud, Switzerland
Founded Date: 7-2
Employees Number: 11-50
Funding Status: Late Stage Venture
Investors Number: 16
Total Funding: CHF26.5M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
info@abionic.com
https://twitter.com/abionic_en
Register and Claim Ownership